Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $713.2 million.

  • Janux Therapeutics' Cash from Financing Activities fell 70.10% to $493,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $388.7 million, marking a year-over-year increase of 18.70%. This contributed to the annual value of $713.2 million for FY2024, which is 1097.75% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Cash from Financing Activities is $713.2 million, which was up 1,097.75% from $59.5 million recorded in FY2023.
  • Janux Therapeutics' Cash from Financing Activities' 5-year high stood at $713.2 million during FY2024, with a 5-year trough of $500,000 in FY2022.
  • Over the past 3 years, Janux Therapeutics' median Cash from Financing Activities value was $59.5 million (recorded in 2023), while the average stood at $257.8 million.
  • In the last 5 years, Janux Therapeutics' Cash from Financing Activities crashed by 99.87% in 2022 and then spiked by 11,809.60% in 2023.
  • Janux Therapeutics' Cash from Financing Activities (Yearly) stood at $11.5 million in 2020, then spiked by 3,254.08% to $386.5 million in 2021, then plummeted by 99.87% to $500,000 in 2022, then skyrocketed by 11,809.60% to $59.5 million in 2023, then spiked by 1,097.75% to $713.2 million in 2024.